What this consultation may focus on.
Reviewing stage, pathology and PSA trend
Discussing systemic treatment when indicated
Monitoring treatment response and side effects
Coordinating care with urology and radiation oncology
Planning treatment for advanced or recurrent disease
Decisions made from the whole clinical picture.
Many prostate cancers are managed primarily by urologists and radiation oncologists, particularly when disease is localised. Medical oncology becomes especially important when systemic treatment is needed for advanced, recurrent or metastatic disease. The plan is based on stage, previous treatment, disease behaviour and individual health factors.
Common reasons patients seek an oncology review.
- Prostate cancer has spread beyond the prostate
- PSA is rising after previous treatment
- Hormonal or other systemic treatment has been recommended
- You need a medical oncology opinion for advanced disease
Questions patients often ask.
Does every prostate cancer patient need chemotherapy?
No. Treatment can include active surveillance, surgery, radiation, hormone therapy and other medicines. Chemotherapy is used in selected situations.
Why is PSA monitored?
PSA is one of several tools used to follow prostate cancer. Its meaning depends on the treatment history and clinical context, so trends should be interpreted with the treating team.
Who is involved in prostate cancer care?
Depending on the stage and treatment plan, care may involve urology, radiation oncology, medical oncology, radiology, pathology and supportive-care teams.